Merck Serono Announces Global Grants Program to Fund Scientific Innovation
Program combines grants portfolio with annual €20 million investment to advance innovation and medical education
The program totals an annual investment of €20 million across all grants programs, highlighting the company’s efforts to promote advances in the field of medicine, addressing recognized gaps in healthcare knowledge, and improving the quality of patient care.
“Merck Serono has a long-standing reputation as a strong advocate for scientific innovation and medical education, believing that both are integral to helping healthcare professionals bring enhanced care to patients,” said Steven Hildemann, Global Chief Medical Officer and Head of Global Medical and Safety at Merck Serono.
The Grants for Innovation in Research identify and fund promising research from across biopharma, including academia, research centers, smaller start-ups and independent researchers. Specific grants focus on areas in which Merck Serono has a strong R&D and commercial presence, including the Grant for Oncology Innovation, Grant for Multiple Sclerosis Innovation, Grant for Fertility Innovation, and Grant for Growth Innovation.
The Grants for Independent Medical Education foster the advancement of medicine, and address recognized gaps in healthcare knowledge, in order to improve patient care. The program includes the launch of an online portal which allows highly transparent and ethical interactions with medical education providers and represents an important milestone in the Merck Serono Medical Education Strategy. Funding is provided to educational institutions such as universities, medical education providers, medical scientists and scientific organizations.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.